Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Apply biomarker testing results to guide treatment decisions for NSCLC
• Differentiate treatment options for advanced NSCLC based on clinical safety and efficacy data
• Integrate clinical evidence and current guideline recommendations on immunotherapies into treatment plans for patients with advanced NSCLC
• Implement interprofessional strategies for reducing disparities in care access and treatment for NSCLC in rural and underserved settings